NURIX THERAPEUTICS, INC. Stock-Based Compensation
NURIX THERAPEUTICS, INC. (NRIX) reported Stock-Based Compensation of $20.79 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-05-31 was $11.39M, a 9.66% increase year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-02-28 was $9.40M, a 7.82% increase year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-11-30 was $9.09M, a 6.79% increase year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-08-31 was $9.77M, a 11.63% increase year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $37.97M, a 11.90% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $33.93M, a 0.76% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $33.67M, a 19.70% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $28.13M, a 78.04% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $20.79M 10-Q · filed 2026-07-09 | $29.88M derived: sum of 3 quarters · filed 2026-07-09 | $39.65M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $9.40M 10-Q · filed 2026-04-08 | $18.49M derived: sum of 2 quarters · filed 2026-04-08 | $28.26M derived: sum of 3 quarters · filed 2026-04-08 | $38.65M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $18.86M derived: sum of 2 quarters · filed 2026-01-28 | $29.24M derived: sum of 3 quarters · filed 2026-07-09 | $37.97M 10-K · filed 2026-01-28 |
| 2025-08-31 | $9.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $20.16M derived: sum of 2 quarters · filed 2026-07-09 | $28.88M 10-Q · filed 2025-10-09 | $37.39M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $10.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $19.11M 10-Q · filed 2026-07-09 | $27.61M derived: sum of 3 quarters · filed 2026-07-09 | $36.37M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $8.72M 10-Q · filed 2026-04-08 | $17.23M derived: sum of 2 quarters · filed 2026-04-08 | $25.98M derived: sum of 3 quarters · filed 2026-04-08 | $34.83M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $17.26M derived: sum of 2 quarters · filed 2026-01-28 | $26.11M derived: sum of 3 quarters · filed 2026-01-28 | $33.93M 10-K · filed 2026-01-28 |
| 2024-08-31 | $8.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $17.60M derived: sum of 2 quarters · filed 2025-10-09 | $25.42M 10-Q · filed 2025-10-09 | $33.45M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $8.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $16.67M 10-Q · filed 2025-07-09 | $24.69M derived: sum of 3 quarters · filed 2026-01-28 | $33.14M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $7.82M 10-Q · filed 2025-04-08 | $15.85M derived: sum of 2 quarters · filed 2026-01-28 | $24.29M derived: sum of 3 quarters · filed 2026-01-28 | $33.01M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $16.47M derived: sum of 2 quarters · filed 2026-01-28 | $25.19M derived: sum of 3 quarters · filed 2026-01-28 | $33.67M 10-K · filed 2026-01-28 |
| 2023-08-31 | $8.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $17.17M derived: sum of 2 quarters · filed 2024-10-11 | $25.65M 10-Q · filed 2024-10-11 | $33.95M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $8.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $17.20M 10-Q · filed 2024-07-11 | $25.50M derived: sum of 3 quarters · filed 2025-01-28 | $32.49M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $8.48M 10-Q · filed 2024-04-10 | $16.78M derived: sum of 2 quarters · filed 2025-01-28 | $23.77M derived: sum of 3 quarters · filed 2025-01-28 | $30.54M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $15.29M derived: sum of 2 quarters · filed 2025-01-28 | $22.06M derived: sum of 3 quarters · filed 2025-01-28 | $28.13M 10-K · filed 2025-01-28 |
| 2022-08-31 | $6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $13.76M derived: sum of 2 quarters · filed 2023-10-12 | $19.83M 10-Q · filed 2023-10-12 | $24.68M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $6.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $12.85M 10-Q · filed 2023-07-13 | $17.69M derived: sum of 3 quarters · filed 2023-07-13 | $22.00M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $6.07M 10-Q · filed 2023-04-13 | $10.91M derived: sum of 2 quarters · filed 2023-04-13 | $15.23M derived: sum of 3 quarters · filed 2023-04-13 | $19.17M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $9.16M derived: sum of 2 quarters · filed 2023-02-09 | $13.10M derived: sum of 3 quarters · filed 2023-02-09 | $15.80M 10-K · filed 2023-02-09 |
| 2021-08-31 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $8.26M derived: sum of 2 quarters · filed 2022-10-06 | $10.96M 10-Q · filed 2022-10-06 | $13.49M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $6.64M 10-Q · filed 2022-07-07 | $9.18M derived: sum of 3 quarters · filed 2022-07-07 | $10.29M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $2.70M 10-Q · filed 2022-04-08 | $5.24M derived: sum of 2 quarters · filed 2022-04-08 | $6.35M derived: sum of 3 quarters · filed 2022-04-08 | $6.83M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $3.65M derived: sum of 2 quarters · filed 2022-01-28 | $4.13M derived: sum of 3 quarters · filed 2022-01-28 | $4.30M 10-K · filed 2022-01-28 |
| 2020-08-31 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $1.59M derived: sum of 2 quarters · filed 2021-10-14 | $1.76M 10-Q · filed 2021-10-14 | $1.93M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $650.00K 10-Q · filed 2021-07-13 | $817.00K derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $176.00K 10-Q · filed 2021-04-13 | $343.00K derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $510.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $343.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |